



Statement of total voting rights and shares forming the company's share capital at the time of publication of the notice prior to the Shareholders' Meeting of May 29, 2020

**Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)**

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date	Number of shares outstanding	Total voting rights	
		Total gross ⁽¹⁾	Total net ⁽²⁾
April 24, 2020	21 947 016	21 947 016	21 693 236

- (1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
- (2) The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in immuno-oncology and chemotherapy, and in other non-oncological molecules.

Contacts

NewCap

Investor relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53